Webinars

CRISPR technology has rapidly evolved from a Nobel Prize-winning discovery to a groundbreaking genetic medicine, exemplified by the recent approval of Casgevy for sickle cell disease. While CRISPR holds immense potential to treat various genetic diseases, manufacturing challenges remain a key hurdle. uBriGene has developed a pioneering in vitro transcription (IVT) sgRNA manufacturing platform that addresses limitations in scalability, quality control, sgRNA length, and environmental sustainability.

What you'll learn in this webinar:

• Insights into uBriGene’s innovative IVT sgRNA manufacturing platform.
• Solutions to overcome technical challenges in traditional solid-phase chemistry workflows.
• How uBriGene’s integrated platforms accelerate clinical success.

RNA-based therapy has been an expanding area of clinical research since the COVID-19 outbreak. Beyond vaccines, RNA therapies are now being developed to treat a growing number of disease indications. The rapid advancement of RNA drugs has taken various forms, including siRNA, sgRNA, mRNA, circRNA, and saRNA.

In this webinar, we will explore the fundamentals of RNA drug development and the critical role of in vitro transcription (IVT) in manufacturing workflows.

What You’ll Learn:

• Basics of RNA drug development and the current landscape.
• Overview of GMP manufacturing workflows for RNA therapies.
• Key aspects of in-process and release testing panels.

This session is perfect for professionals looking to deepen their understanding of RNA manufacturing processes and ensure their workflows are GMP-compliant.

The goal of this webinar is to:

• Understand the basics of Lentiviral Vector (LV): definition and characteristics of LV, and their mechanism of action in gene-modified cell therapies.
• Explore current manufacturing approaches for LV: an overview of existing platforms and technologies, as well as key considerations in LV production scalability and efficiency.
• Discuss strategies to accelerate LV deployment in cell therapy: the importance of early identification of critical raw materials, and criteria for selecting a proven manufacturing platform, also impact on time-to-market and therapeutic accessibility.

In the first presentation, you will gain a comprehensive understanding of CAR-T therapies, including:

• The general requirements for the development of CAR-T therapies
• General approaches to gene modification of T-cells
• High level discussion of GMP manufacturing workflows
• Regulatory considerations for clinical application of these therapies